Within a cellular clinical viewpoint, biochemicalpharmacy Relafen 750 (Naproxen) exhibits distinct properties . It functions primarily as a non-copyrightal drug , preferentially suppressing cyclooxygenase-2 (COX-2), an enzyme participating in prostaglandin synthesis . This targeted inhibition generates decreased inflammation and discomfort , provid